Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Common Equity (2016 - 2026)

Cartesian Therapeutics has reported Common Equity over the past 12 years, most recently at -$148.1 million for Q1 2026.

  • Quarterly Common Equity fell 579.78% to -$148.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$148.1 million through Mar 2026, down 579.78% year-over-year, with the annual reading at -$126.2 million for FY2025, 1755.92% down from the prior year.
  • Common Equity was -$148.1 million for Q1 2026 at Cartesian Therapeutics, down from -$126.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $93.8 million in Q4 2022 and troughed at -$440.2 million in Q4 2023.
  • The 5-year median for Common Equity is -$2.5 million (2025), against an average of -$27.9 million.
  • Year-over-year, Common Equity soared 2222.36% in 2022 and then tumbled 4866.49% in 2025.
  • A 5-year view of Common Equity shows it stood at $93.8 million in 2022, then plummeted by 569.14% to -$440.2 million in 2023, then skyrocketed by 98.45% to -$6.8 million in 2024, then tumbled by 1755.92% to -$126.2 million in 2025, then decreased by 17.33% to -$148.1 million in 2026.
  • Per Business Quant, the three most recent readings for RNAC's Common Equity are -$148.1 million (Q1 2026), -$126.2 million (Q4 2025), and -$35.8 million (Q3 2025).